Share Twitter LinkedIn Facebook Email Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in premenopausal, metastatic breast cancer.
2025 Breast Cancer Updates: Dr. Evanthia Roussos Torres on Biomarkers, Immunotherapy, and the Future of Treatment – MOASC Breast 6 Mins Read
FDA Approves Datopotamab Deruxtecan / Datroway from Eli Lilly in Treatment for Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer Breast 2 Mins Read
